Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Di Leo

Showing results (61-70 of 187) with videos related to

Pageof 19
Sort By:
Critical Reviews in Oncology/Hematology|March 6, 2016
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practiceValentina Sini, Saverio Cinieri, Pierfranco Conte, et al.
Therapeutic Advances in Medical Oncology|June 15, 2018
The role of abemaciclib in treatment of advanced breast cancerAmelia McCartney, Erica Moretti, Giuseppina Sanna, et al.
The Breast Journal|July 17, 2019
Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institutionGiacomo Barchiesi, Amelia McCartney, Chiara Biagioni, et al.
Cancer Treatment Reviews|December 28, 2020
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancerIlenia Migliaccio, Martina Bonechi, Amelia McCartney, et al.
Breast (Edinburgh, Scotland)|January 12, 2018
First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM studyAngelo Di Leo, Guy Jerusalem, Roberto Torres, et al.
Breast Care (Basel, Switzerland)|December 14, 2017
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of ResponseCristina Guarducci, Martina Bonechi, Giulia Boccalini, et al.
Cancer Treatment Reviews|February 2, 2019
The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise reviewLorenzo Rossi, Amelia McCartney, Irene De Santo, et al.
Clinical Breast Cancer|July 31, 2019
Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast CancerLorenzo Rossi, Amelia McCartney, Emanuela Risi, et al.
Current Medical Research and Opinion|January 26, 2010
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancerBeth Sherrill, Angelo Di Leo, Mayur M Amonkar, et al.
Breast (Edinburgh, Scotland)|October 1, 2013
The continued evidence from overviews: what is the clinical utility?Natalie Turner, Laura Biganzoli, Luca Malorni, et al.
Pageof 19

Showing results (61-70 of 187) with videos related to

Sort By:
Pageof 19
Critical Reviews in Oncology/Hematology|March 6, 2016
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practiceValentina Sini, Saverio Cinieri, Pierfranco Conte, et al.
Therapeutic Advances in Medical Oncology|June 15, 2018
The role of abemaciclib in treatment of advanced breast cancerAmelia McCartney, Erica Moretti, Giuseppina Sanna, et al.
The Breast Journal|July 17, 2019
Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institutionGiacomo Barchiesi, Amelia McCartney, Chiara Biagioni, et al.
Cancer Treatment Reviews|December 28, 2020
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancerIlenia Migliaccio, Martina Bonechi, Amelia McCartney, et al.
Breast (Edinburgh, Scotland)|January 12, 2018
First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM studyAngelo Di Leo, Guy Jerusalem, Roberto Torres, et al.
Breast Care (Basel, Switzerland)|December 14, 2017
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of ResponseCristina Guarducci, Martina Bonechi, Giulia Boccalini, et al.
Cancer Treatment Reviews|February 2, 2019
The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise reviewLorenzo Rossi, Amelia McCartney, Irene De Santo, et al.
Clinical Breast Cancer|July 31, 2019
Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast CancerLorenzo Rossi, Amelia McCartney, Emanuela Risi, et al.
Current Medical Research and Opinion|January 26, 2010
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancerBeth Sherrill, Angelo Di Leo, Mayur M Amonkar, et al.
Breast (Edinburgh, Scotland)|October 1, 2013
The continued evidence from overviews: what is the clinical utility?Natalie Turner, Laura Biganzoli, Luca Malorni, et al.
Pageof 19